Research programme: VLX 2000 - Veralox Therapeutics
Alternative Names: VLX-2000Latest Information Update: 07 May 2024
At a glance
- Originator Veralox Therapeutics
- Class Anti-inflammatories; Antihyperglycaemics; Small molecules
- Mechanism of Action 12-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 22 Mar 2024 Preclinical trials in Inflammation in USA (unspecified route), prior to March 2024 (Veralox Therapeutics pipeline, March 2024)